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Background: The molecular players regulating platelet life span are largely unexplored.
Results: Proteasome inhibition induced apoptotic changes in platelets associated with a rise in active Bax and significant drop
in platelet life span.
Conclusion: Proteasome plays a crucial role in delimiting platelet life span through constitutive elimination of the conforma-
tionally active Bax.
Significance: The findings bear relevance in clinical settings where proteasome is therapeutically inhibited.
Limit of platelet life span (8–10 days) is determined by the
activity of a putative “internal clock” composed of Bcl-2 family
proteins, whereas the role of other molecular players in this
process remains obscure. Here, we sought to establish a central
role of proteasome in platelet life span regulation. Administra-
tion of mice with inhibitors of proteasome peptidase activity
induced significant thrombocytopenia. Thiswas associatedwith
enhanced clearance of biotin-labeled platelets from circulation
and reduction in average platelet half-life from 66 to 37 h. Cells
pretreated in vitro with proteasome inhibitors exhibited aug-
mented annexin V binding and a drop in mitochondrial trans-
membrane potential indicative of apoptotic cell death and
decreased platelet life span. These cells were preferentially
phagocytosed by monocyte-derived macrophages, thus linking
proteasome activity with platelet survival. The decisive role of
proteasome in this process was underscored from enhanced
expression of conformationally active Bax in platelets with
attenuated proteasome activity, which was consistent with pro-
apoptotic phenotype of these cells. The present study estab-
lishes a critical role of proteasome indelimiting platelet life span
ostensibly through constitutive elimination of the conforma-
tionally activeBax.These findings bear potential implications in
clinical settings where proteasome peptidase activities are ther-
apeutically targeted.
Platelets are anucleate circulating cells that aremajor players
in the process of hemostasis and thrombosis (1, 2). Platelets are
produced from megakaryocytes and released into circulation,
where they have a defined life span of 7–10 days in human (4–5
days in mouse), following which they are selectively cleared by
the reticuloendothelial system (3). Thus, the steady-state plate-
let count in circulation is the balance between platelet biogen-
esis and clearance (4). Our knowledge of molecular mecha-
nisms controlling platelet life span has so far been limited. The
earlier hypothesis to explain platelet senescence at steady-state
had been the “multiple-hit” model, which proposed restricted
endurance of circulating platelets to “hits” inflicted fromwithin
environment, before platelets are recognized and cleared by
macrophages (5, 6).
In a significant recent study platelet life span was demon-
strated to be determined by putative internal clock based on
opposing activities of anti- and pro-apoptotic Bcl-2 family pro-
teins, particularly Bcl-XL, Bak, and Bax (7, 8). However, factors
and processes regulating ticking of this clock are yet to be
defined.
The 26 S proteasome is a multiprotein complex responsible
for proteolysis of ubiquitinated peptides (9). Expressed ubiqui-
tously, the ubiquitin-proteasome system is composed of a 20 S
core cylinder endowed with peptidase activities and capped at
each endwith a 19 S regulatory particle (9). Proteasome activity
is known to decline steadily upon aging, leading to accumula-
tion of misfolded proteins, the hallmark of age-related disor-
ders (10). Surprisingly, there have been few reports exploring
the role of proteasome in platelets (11, 12). We have recently
demonstrated calcium-mediated up-regulation of proteasomal
activity in stimulated platelets (13). In the present study we
demonstrate a critical role of proteasome in the regulation of
platelet life span. We show that attenuation of proteasome
activity significantly shortens life span of platelets associated
with accumulation of conformationally active Bax and phago-
cytic clearance of the cells by macrophages.
EXPERIMENTAL PROCEDURES
ABT-737 was purchased from Selleck Chemicals. Anti-
CD61-PE and annexin V-FITCwere fromBDBiosciences. Pro-
teasome inhibitors PSI2 (Z-Ile-Glu(OtBu)-Ala-Leu-CHO), PSII
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2 The abbreviations used are: PSI, (Z-Ile-Glu(OtBu)-Ala-Leu-CHO); PSII, (Z-Leu-
Leu-Phe-CHO); AC-DEVD-AMC, acetyl-Asp-Glu-Val-Asp-7-amido-4-meth-
ylcoumarin; BSA, bovine serumalbumin; CCCP, carbonyl cyanide 3-chloro-
phenylhydrazone; DMSO, dimethyl sulfoxide; EDTA, ethylenediamine
tetraacetic acid; EGTA, ethyleneglycol tetraacetic acid; H2DCFDA, 6-car-
boxy-2,7-dichlorodihydrofluorescein; JC-1, 5,5-6,6-tetrachloro-1,1,3,3-
tetraethylbenzimidazolylcarbocyanine iodide; MDMs, monocyte-derived
macrophages;NHS-biotin,N-hydroxysuccinimidobiotin;PBS,phosphatebuff-
ered saline; PBMCs, peripheral blood mononuclear cells; PRP, platelet-rich
plasma; PS, phosphatidylserine; m, mitochondrial transmembrane
potential.
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(Z-Leu-Leu-Phe-CHO), MG132 (Z-Leu-Leu-Leu-CHO), and
calpeptin were procured from Calbiochem. Whereas PSI and
PSII specifically inhibit chymotryptic activity of 20 S protea-
some, MG132 prevents degradation of ubiquitinated pro-
teins by targeting 26 S proteasome. Bortezomib (Bortecad)
was purchased from Cadila Pharmaceuticals. N-Hydroxy-
succinimidobiotin (NHS-biotin), PE-streptavidin, 5,5-6,6-
tetrachloro-1,1,3,3 tetraethylbenzimidazolylcarbocyanine
iodide (JC-1), thiazole orange, carbonyl cyanide 3-chlorophenyl-
hydrazone (CCCP), 6-carboxy-2,7-dichlorodihydrofluorescein
(H2DCFDA), acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcou-
marin (AC-DEVD-AMC), apyrase, EGTA, EDTA, sodium
orthovanadate, acetylsalicylic acid, bovine serum albumin (BSA)
(fraction V), TritonX-100, protease inhibitors, dimethylsulfox-
ide (DMSO), oleuropein, mouse monoclonal anti-Bax (6A7),
anti-Bax (2D2), and rabbit polyclonal anti-Bak were purchased
from Sigma. Mouse monoclonal anti-ubiquitin was procured
from Santa Cruz Biotechnology. Calcein-AM, Fura-2/AM and
t-butoxycarbonyl-Leu-Metchloromethylcoumarin were from
Invitrogen. RPMI 1640 medium was purchased from HiMedia.
Reagents for electrophoresis were products of Merck. PVDF
membranes and rabbit polyclonal active anti-caspase-3 were
fromMillipore. SuperSignalWest Pico chemiluminescent sub-
strate was from Pierce. Mouse monoclonal anti-cytochrome c
and horseradish peroxidase (HRP)-labeled secondary antibod-
ies were purchased from Transduction Laboratories and Ban-
galore Genei, respectively. All other reagents were of analytical
grade. Milli-Q grade, type 1, deionized water (Millipore) was
used for preparation of solutions.
Platelet Preparation—Platelets were isolated from fresh
human blood by differential centrifugation, as described (14).
Briefly, blood from healthy volunteers was collected in citrate
phosphate-dextrose adenine and centrifuged at 180 g for 10
min. Platelet-rich plasma thus obtained was incubated with 1
mM acetylsalicylic acid for 15 min at 37 °C. After addition of
EDTA (5 mM), platelets were sedimented by centrifugation at
800  g for 15 min. Cells were washed in buffer A (20 mM
HEPES, 138 mM NaCl, 2.9 mM KCl, 1 mM MgCl2, 0.36 mM
NaH2PO4, 1 mM EGTA, supplemented with 5 mM glucose and
0.6 ADPase unit of apyrase/ml, pH 6.2) and were finally resus-
pended in buffer B (20 mM HEPES, 138 mM NaCl, 2.9 mM KCl,
1 mM MgCl2, 0.36 mM NaH2PO4, 5 mM glucose, pH 7.4). The
final cell countwas adjusted to 0.5–0.8 109/ml. All stepswere
carried out under sterile conditions, and precautions were
taken to maintain the cells in resting condition.
Platelet Clearance Analysis—Mice were injected in tail vein
with 600 mg of NHS-biotin and either DMSO (control) or PSI
(0.3mg/kg) (treated) (15). At various time points 50l of retro-
orbital blood was drawn from both control as well as treated
mice, mixed with 200 l of buffered saline-glucose-citrate
buffer (116 mM NaCl, 13.6 mM trisodium citrate, 8.6 mM
Na2HPO4, 1.6 mM KH2PO4, 0.9 mM EDTA, 11.1 mM glucose),
and followed by 1 ml of balanced salt solution (149 mM NaCl,
3.7 mM KCl, 2.5 mM CaCl2, 1.2 mMMgSO4, 7.4 mM HEPES, 1.2
mM KH2PO4, 0.8 mM K2HPO4, 3% bovine calf serum). Cells
were pelleted at 1400 g for 10min, and resuspended in 300l
of sheath fluid. They were stained with FITC-conjugated rat
anti-CD41, which label only platelets, followed by PE-strepta-
vidin for 1 h on ice, washed in balanced salt solution, and ana-
lyzed by flow cytometry to determine the fraction of platelet
population labeled with PE (7).
Labeling of Reticulated Platelets—Mice were injected intra-
venously with either DMSO or PSI as described above. Blood
was collected from retro-orbital plexus ofmice at different time
points (0, 24, 48, 72, and 96 h). Staining for reticulated platelets
was carried out by incubation of 5 l of blood with 50 l of
thiazole orange (0.1mg/ml in phosphate-buffered saline (PBS))
and 1l of PE-conjugatedCD41 antibody in the dark for 15min
at room temperature, followed by fixation with 1ml of parafor-
maldehyde (1%) in PBS (7). Cells were washed with PBS, resus-
pended in 300 l of sheath fluid, and analyzed by flow cytom-
etry. After appropriate compensation, fluorescence data were
collected using four-quadrant logarithmic amplification.
Cytofluorometric Analysis ofMitochondrial Transmembrane
Potential—Mitochondrial transmembrane potential (m)was
measured using the potential-sensitive fluorochrome JC-1,
which selectively moves across polarized mitochondrial mem-
brane and forms aggregates (red). As membrane potential col-
lapses, the fluorescence changes from red to green due to
release of monomeric dye (16). To study m, platelets were
pretreated with PSI (20 M), PSII (20 M), MG132 (10 M),
CCCP (30 M), or DMSO (vehicle) for 30 min, followed by
incubation with 2 M JC-1 for 15 min at 37 °C in the dark. Cells
were washed in PBS, and JC-1 fluorescence was analyzed in FL1
and FL2 channels of flow cytometer (FACSCalibur; BD Biosci-
ences) for detection of dye monomer and aggregates, respec-
tively. The ratio of red to green (FL2/FL1) fluorescence
reflected m.
Flow Cytometric Measurement of Reactive Oxygen Species
(ROS)—Platelets were treated with proteasome inhibitors or
vehicle as above, washed with PBS, and incubated with
H2DCFDA (1 M) for 30 min at 37 °C in the dark. Cells were
next washed twice with PBS and analyzed by flow cytometry as
described previously (16).
Measurement of Annexin V Binding by Flow Cytometry—
Platelets (1 108 cells in 100l) were incubated at 37 °C for 30
min in the presence of proteasome inhibitors or vehicle as
stated above. For positive control the washed platelets were
treated with thrombin (1 unit/ml) for 10 min without stirring.
Then an equal amount of 4% paraformaldehyde was added to
the cells and incubated for 30min, whichwas followed bywash-
ing. Postfixed resuspended platelets were labeled with 5 l of
PE-labeled anti-CD61 antibody and 10 l of FITC-labeled
annexin V in the presence of 5 mM CaCl2 to promote binding.
Samples were incubated for 30 min at room temperature in the
dark and analyzed on the flow cytometer (16). After compensa-
tion between FITC and PE, all fluorescence data were collected
using four-quadrant logarithmic amplification. Data from
10,000 CD61-positive events were collected for each sample.
Isolation of Mitochondria-rich and Cytosolic Fractions—
Platelets suspended inmitochondria extraction buffer (225mM
mannitol, 75 mM sucrose, 0.1 mM EGTA, 1 mg/ml fatty acid-
free BSA, 10mMHEPES-KOH, 2mM sodiumorthovanadate, 21
M leupeptin, 2 mM phenylmethylsulfonyl fluoride, 20M pep-
statin A, and 0.56 unit of trypsin inhibitor/ml of aprotinin, pH
7.4) were lysed by freezing in liquid nitrogen for 1min followed
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by thawing at 37 °C for 3 min (17). The freeze-thaw sequence
was repeated for twomore cycles. The lysate was centrifuged at
700 g for 10min at 4 °C, and pellet was discarded. The super-
natant was further centrifuged at 15,000 g for 10 min at 4 °C.
The pellet was regarded as the mitochondria-rich fraction, and
the supernatant was the mitochondria-free cytosolic fraction.
Caspase-3 Activity Assay—To determine cytosolic caspase-3
activity, samples were pretreated with 10, 25, and 50 M of PSI
or vehicle (DMSO) and lysed with equal amount of 2 radio-
immune precipitation assay (RIPA) buffer. After a 10-min incu-
bation in ice, an equal volume of 2 substrate buffer (20 mM
HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, 5 mM DTT, and 10
M caspase substrate AC-DEVD-AMC) was added to each
lysate and further incubated for 30min at 37 °C (16). Caspase-3
activity was determined from the extent of cleavage of fluoro-
genic substrate measured at 460 nm emission (excitation, 360
nm). In other experiments active caspase-3 was detected by
Western blot analysis in cell lysate using specific antibody.
Calpain Activity Assay—Intracellular calpain activity was
measured as described previously (18). Washed human plate-
lets in a 96-well plate were exposed to DMSO or PSI for 30 min
and then loaded with t-butoxycarbonyl-Leu-Metchlorometh-
ylcoumarin (10 M). After a 30-min incubation, cellular fluo-
rescence was quantified with a fluorescence microplate reader
(BioTek model FLx800) at 37 °C using 351-nm excitation and
430-nm emission filters.
Measurement of Intracellular Free Calcium—Intracellular
calciummeasurements were carried out in platelets pretreated
with either DMSO (vehicle) or different concentrations of PSI
using Fura-2/AM dye as described previously (14). Fluores-
cence was recorded using Hitachi fluorescence spectropho-
tometer (model F-2500) and intracellular calcium levels were
obtained using FL Solutions software.
Inmunoprecipitation—Ubiquitinated platelet proteins were
immunoprecipitated as described earlier (16). Briefly, 500 l of
platelet suspensionwas lysed and immunoprecipitated by incu-
bation with 2g of anti-ubiquitin antibody and 25l of protein
A-agarose overnight at 4 °C on a rocking platform. It was
washed three times with 500 l of 2 RIPA buffer, and the
pellet was subjected to polyacrylamide gel electrophoresis
(PAGE).
Western Blotting—Proteins were separated by 13% SDS- or
native-PAGE and transferred electrophoretically onto PVDF
membrane (0.8 mA/cm2, 2 h) in a semidry blotter (TE 77 PWR;
GEHealthcare) for subsequent probing as described previously
(14). Blots were incubated for 1 h with 5% (w/v) BSA in Tris-
buffered saline containing 0.05% Tween 20 (TBST) to block
residual protein binding sites. Membranes were incubated
overnight at 4 °C with the primary antibodies (anti-Bax (6A7),
1:500; anti-Bax (2D2), 1:1000; anti-Bak, 1:1000; anti-caspase-3,
1:200; and anti-cytochrome c, 1:500). Blots were incubated
with the appropriate HRP-conjugated secondary antibody
(diluted 1:10,000) and exposed to enhanced chemilumines-
cence reagents for 5 min. Blots were exposed to photographic
films and densitometrically scanned. For protein loading con-
trol, membranes containing whole cell lysates were reprobed
with the anti-actin antibody (1:1000).
Monocyte Isolation, Culture, and Phagocytic Recognition of
Platelets—Human monocytes were isolated and cultured as
described (17, 19). Briefly, blood from healthy donors was col-
lected in citrate, and peripheral blood mononuclear cells
(PBMCs) were isolated usingHysep, according to themanufac-
turer’s instructions.Monocytes were further isolated by plating
the PBMCs on polystyrene-coated tissue culture flasks for 4 h at
37 °C, followed by three washes with PBS to remove nonadher-
ent lymphocytes. Monocytes (250,000 in 500-l volume) were
then plated on 6-well plates in RPMI 1640 medium supple-
mented with 10% fetal bovine serum and cultured for 7 days to
obtain the monocyte-derived macrophages (MDMs). Platelets
labeled with calcein-AM were incubated with a monolayer of
autologousMDMs for 45min. Following the incubation period,
the phagocyte monolayer was washed free of noninteracting
platelets, and any adherent platelets were removed by treat-
ment with trypsin at 37 °C for 5min followed by 5mM EDTA at
4 °C.MDMswere recovered by trypsin/EDTA treatment for 15
min at 37 °C and subjected to flow cytometric and epifluores-
cent microscopic analysis.
Statistical Methods—Standard statistical methods were
used. Parametric methods (t test) were used for evaluation, and
tests were considered significant at p 0.05 (two-tailed tests).
Data are presented as means  S.D. of at least five individual
experiments from different blood donors.
RESULTS
Proteasome Inhibition Leads to Decreased Platelet Life Span—
Platelet life span is determined by opposing activities of anti-
and pro-apoptotic Bcl-2 family proteins (7, 8). As proteasomal
activity in tumor cells influences cellular level of these proteins
(20–22), we investigated whether proteasome has a role in reg-
ulating platelet lifespan in vivo. Intravenous administration of
PSI (0.3 mg/kg) and bortezomib (0.1 mg/kg) in mice led to sig-
nificant lowering of platelet count from 1.8  103/l to 0.8 
103/l and 0.9 103/l, respectively (n 5), suggestive of close
relationship between proteasome inhibition and induction of
thrombocytopenia (Fig. 1A).
Reduction in platelet count could either be due to an increase
in platelet clearance or decreased platelet production. To study
possible changes in platelet clearance we conjugated mice
platelets with biotin by intravenous administration of NHS-
biotin and tracked the labeled platelets ex vivo by incubating
cells with PE-streptavidin (7). Consistent with an earlier obser-
vation by Berger et al. (23), platelet half-life (t1⁄2-clearance of
50%biotin-conjugated platelets) was found to be 66 h in control
mice. Platelet half-life dropped significantly to 37 h and 32 h in
mice administered with PSI and bortezomib, respectively (Fig.
1B). Oleuropein, which has been recently demonstrated to be a
potential proteasome activator, caused a small but consistent
increment in platelet half-life to 72 h (Fig. 1B).
Thiazole orange stains young reticulated platelets and hence
reflects adequacy of platelet generation by bone marrow (7).
Platelets exhibited a steady time-dependent increase in thiazole
orange staining (11-fold rise in 96 h) in mice administered with
PSI, whereas those in control mice remained significantly less
stainedwithminor increment observed at 96 h (Fig. 1,C andD).
This was consistent with progressive expansion in young plate-
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let population and increased platelet generation as a conse-
quence of enhanced platelet clearance in PSI-administered
mice. Thus, proteasome inhibition in vivo increases platelet
clearance and limits its life span in circulation.
Proteasome Inhibition Induces Apoptosis-like Changes in
Human Platelets Associated with Up-regulation of Bax—Bort-
ezomib, a highly selective inhibitor of proteasomal peptidase
activity, has been employed in cancer therapy for its ability to
induce apoptosis in tumor cells (24). To determine whether
proteasome inhibition regulates platelet life span through
induction of apoptosis, we investigated the effect of different
inhibitors of proteasome activity on m and surface exposure
of phosphatidylserine (PS) in mice platelets in vivo and human
platelets in vitro. JC-1, a lipophilic cation, was employed to
determine alterations in m. As expected, a high aggregate to
monomer fluorescence ratio (FL2/FL1) of the fluor was
observed in untreated (control) washed human platelets indic-
ative of stabilized m, which dropped drastically in CCCP
(protonophore)-treated platelets (Fig. 2A). Incubation of plate-
lets with different proteasome inhibitors (PSI, 20 M; PSII, 20
M; MG132, 10 M; and bortezomib, 25 M) was associated
with significant decrements in m (by 50, 62.5, 55, and 70%,
respectively) compared with control (Fig. 2A). Consistent with
above results, PSI or bortezomib, when administered intrave-
nously to mice, evoked a dose-dependent drop in m starting
1 h after treatment ex vivo, whereas those from vehicle-treated
mice exhibited stable m (Fig. 2, C and E).
Externalization of PS, an anionic phospholipid, from the
inner leaflet to outer layer of cell membrane is an invariable
early feature in the apoptotic process (16). FITC-annexin V
binding to cell surface was studied next to detect platelets
undergoing apoptosis. As expected, surface membrane was
found to be significantly enriched with PS in thrombin-stimu-
lated platelets compared with the resting cells. Remarkably,
pretreatment of platelets with different proteasome inhibitors,
PSI, PSII, MG132, and bortezomib resulted in dramatic
increase (by 4-, 5-, 3-, 4 and 5-fold, respectively) in annexin V
binding compared with the untreated (control) cells, indicative
of induction of apoptosis-like changes upon proteasome inhi-
bition (Fig. 2B). A comparable dose-dependent increase in
annexin V binding was also observed in mouse platelets after
administering mice with PSI and bortezomib (Fig. 2, D and F).
Because apoptosis is known to be associated with cellular ROS
generation (16, 25, 26), we sought to determine whether pro-
teasome inhibition induced ROS production in platelets. Using
the cell-permeable dye H2DCFDA, ROSwas found to be signif-
icantly enhanced (by 3.8-, 3.6-, and 6.1-fold) in platelets treated
with PSI, MG132, and PSII, respectively (data not shown),
which further validated the reciprocal relationship between
proteasome activity and induction of platelet apoptosis.
FIGURE 1. A, platelet count in control, PSI-, and bortezomib-treated mice at different time points. B, proportion of biotinylated platelets (percentage) in
peripheral blood sample drawn fromDMSO (vehicle), PSI (0.3mg/kg), bortezomib (0.1mg/kg), or oleuropein (1.5mg/kg) pretreatedmice 0, 24, 48, 72, and 96h
after administration of NHS-biotin. t1⁄2 represents platelet half-life in hours. C, representative flow cytometric profiles of thiazole orange-stained platelets 0, 24,
48, 72, and 96 h after a single dose of DMSO (upper row) or PSI (0.3 mg/kg) (lower row). Percentage values indicated in upper panels correspond to younger
(reticulated) platelets among entire platelet population. D, quantitative representation of results shown in C. Data are representative of five different experi-
ments and are expressed as mean S.D. (error bars).
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Next, we searched for putative molecular mediators of apo-
ptosis in platelets treated with proteasome inhibitors. Early in
the process of apoptosis Bax, the pro-apoptotic member of
Bcl-2 family, is known to undergo conformational change and
translocate to themitochondrial membrane (27).We evaluated
changes in levels of both total Bax and conformationally
changed active Bax in platelets with or without proteasomal
inhibition. Active Bax was detected by immunoblotting with an
antibody (clone 6A7), which specifically detects Bax in its con-
formationally altered state. As expected BH3-mimetic ABT737
induced significant Bax activation in platelets (Fig. 3A). We
found progressive increments in conformationally active Bax
(by 11-, 25-, and 27-fold) but not total Bax in platelets pre-
treated with increasing concentrations of PSI (10, 25, and 50
M, respectively) (Fig. 3, A and B), indicative of its accumula-
tion upon proteasome inhibition. Active Bax was also found to
translocate to platelet mitochondrial fraction under identical
experimental condition when proteasome was inhibited by PSI
in a concentration-dependent manner (Fig. 3A). No change in
the level of other pro-apoptotic Bcl-2 family protein Bak was
observed upon proteasomal inhibition (Fig. 3A).
We then looked for ubiquitination of conformationally active
Bax in unstimulated platelets. Ubiquitinated proteins were
immunoprecipitated from platelet cell lysate and probed using
anti-Bax (6A7) antibody. We observed multiple bands of high
molecular weight typical of polyubiquitinated proteins. Fur-
ther, significantly greater levels of polyubiquitinated active Bax
were observed in PSI-treated platelets (Fig. 3, C and D). Thus,
active Bax was found to be constitutively targeted to protea-
somal degradation by polyubiquitination.
To establish the causal role of active Bax in regulating platelet
life span, the effect of proteasome inhibitor was observed in
platelets preincubated with V5 peptide, a Bax inhibitor. PSI-
induced drop in m was reversed by 14, 23, and 54% with 25,
50, and 100 MV5 peptide, respectively (Fig. 3E). In agreement
with this, preadministration of mice with V5 peptide (2 mg/kg)
by an intravenous route also caused 38% amelioration of the
drop in platelet life span induced by PSI (Fig. 3F).
Platelet Cell Death upon Proteasome Inhibition Is Caspase-
independent—The pro-apoptotic members of Bcl-2 family
induce release of mitochondrial cytochrome c into cytosol,
which eventually leads to caspase-3 activation through consti-
tution of apoptosome complex with Apaf-1 and caspase-9 (28).
Because proteasome inhibition was associated with apoptosis-
like features such as PS exposure and accumulation of active
Bax in platelets, we sought to determine caspase-3 activity
under identical experimental condition. As reported earlier
(16), ABT737 induced significant release of mitochondrial
cytochrome c as well as caspase-3 activation in platelets (Fig.
4A). However, we neither detected cytochrome c in extramito-
chondrial cytosolic fraction (Fig. 4A, top), nor could we record
up-regulation in caspase-3 activity (Fig. 4, A, bottom, and B) in
FIGURE 2. Study of apoptotic features in platelets following proteasomal inhibition. A and B, mitochondrial transmembrane potential (FL2/FL1 ratio) (A),
andPS exposure (FITC-annexin Vbinding) (B) in platelets pretreatedwithproteasome inhibitors (PSI, 20M; PSII, 20M;MG132, 10M; andbortezomib, 25M),
CCCP (30M), thrombin (1 unit/ml) or DMSO (RP or control), as indicated. C andD, changes inmitochondrial transmembrane potential (C) and FITC-annexin V
binding (D) with time observed in platelets frommice 0, 24, 48, 72, and 96 h after injection of DMSO (control), PSI, or bortezomib (bort.). E and F, mitochondrial
transmembranepotential (E) and FITC-annexin Vbinding (F) inmice platelets 1 h after intravenous treatmentwithDMSO (control), PSI, or bortezomib. Data are
representative of five different experiments and are expressed as mean S.D. (error bars). *, p 0.05 compared with DMSO-pretreated platelets; #, p 0.05
compared with 0 h platelets.
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platelets exposed to increasing doses of PSI (10, 25, and 50M).
These observations underscore the possibility of caspase-inde-
pendent cell death pathway operational in platelets (19) as well
as monocytes (29, 30), as described earlier. Studies including
our own have suggested the role of calpain, a calcium-depen-
dent thiol protease, in mediating cell death in platelets espe-
cially upon storage (19, 31). Hence, we looked for the relation-
ship between proteasome inhibition and calpain activity in
platelets. Platelets pretreated with PSI were found to exhibit
higher calpain activity than their vehicle-treated counterparts
(Fig. 4C). Pretreatment of cells with PSI also induced release of
cytosolic free calcium from platelet intracellular stores in a
dose-dependentmanner (Fig. 4D), which is consistentwith pre-
vious reports of Bax regulating release of calcium from the
stores in endoplasmic reticulum (32). The effect of proteasome
inhibition on platelet m and PS exposure was examined in
the presence of calpeptin, a specific calpain inhibitor, to estab-
lish the role of calpain in mediating cell death. Calpeptin
brought about 39 and 24% reversal of PSI-induced PS external-
ization and drop in m, respectively (Fig. 4, E and F). Thus,
platelet cell death upon proteasome inhibition is Bax-depen-
dent and attributable to calpain activation.
Proteasome Inhibition Is Associated with EnhancedUptake of
Platelets by Macrophages—Platelets undergoing apoptosis-like
changes are known to be removed by phagocytes in the reticu-
loendothelial system (33). Hence, we evaluated macrophage-
assisted clearance of platelets following proteasomal inhibition.
Calcein-stained platelets, either pretreated with PSI (20 M) or
DMSO, were incubated with amonolayer of autologousmono-
cyte-derived adherent human macrophages for 45 min. The
phagocyte monolayer was next washed free of noninteracting
platelets and subjected to flow cytometry as well as epifluores-
cence microscopy to examine phagocytic uptake of platelets by
macrophages.
Macrophages were gated and analyzed by flow cytometry for
associated fluorescence (FL1). They exhibited significantly
higher calcein fluorescence following incubation with PSI-
treated fluorescent platelets, which was reflective of enhanced
phagocytic uptake of treated platelets (Fig. 5A). This finding
was further corroborated from epifluorescence microscopy of
macrophages. Significantly higher mean fluorescence intensity
(per high power field) was found to be associated with macro-
phages co-incubatedwith PSI-treated platelets than the control
FIGURE 3. A, Western blots showing expression levels of active Bax, total Bax, and Bak in whole cell lysate or mitochondrial fraction prepared from platelets
pretreated with DMSO (RP), PSI, or ABT737. B, quantitative representation of active Bax levels in platelet whole cell lysates as determined by densitometry of
Western blots.C, Western blots showing expression levels of ubiquitinated active Bax immunoprecipitated fromplatelets pretreatedwithDMSO (RP) or PSI for
30 min. D, quantitative representation of expression levels in Western blots shown in C as determined by densitometry. E, mitochondrial transmembrane
potential (FL2/FL1 ratio) in PSI-treatedplateletswithorwithoutpreincubationwithV5peptide as indicated. F, proportionofbiotinylatedplatelets (percentage)
in peripheral blood samples drawn frommice treated with DMSO alone (control) PSI (0.3 mg/kg) alone, or a combination of V5 peptide (2 mg/kg) and PSI (0.3
mg/kg) 0, 24, 48, 72, and 96h after administration ofNHS-biotin. t1⁄2 represents platelet half-life in hours. *, p 0.05 comparedwithDMSO-pretreatedplatelets.
Data are representative of five different experiments and are expressed as mean S.D. (error bars).
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FIGURE 5. Phagocytic uptake of platelets by autologous macrophages. A, flow cytometry of macrophages co-incubated with calcein-labeled platelets
pretreated eitherwith PSI (20M) or DMSO (control). B, epifluorescencemicroscopy ofmacrophages co-incubatedwith platelets pretreated eitherwithDMSO
(a) or PSI (20 M) (b). Panels a and b represent corresponding phase-contrast micrographs. Scale bars, 10 m. Data are representative of five different
experiments.
FIGURE 4. A, Western blot analysis showing levels of cytochrome c and active caspase-3 in platelet whole cell lysate ormitochondria-free cytosolic suspension,
as indicated, 30min after treatment of platelets with DMSO (RP), PSI, or ABT737. B and C, caspase-3 activity (B) and calpain activity (C) as determined from the
extent of cleavage of fluorogenic substrate AC-DEVD-AMC or t-butoxycarbonyl-Leu-Metchloromethylcoumarin, respectively, in platelets pretreated with
DMSO (RP), PSI, or ABT737.D, intracellular calcium levels represented as ratio of fluorescence intensity at 340 nm to that at 380 nmmeasured inwashedhuman
platelets labeled with Fura-2/AM dye, 1 min after treatment with DMSO or PSI. E and F, mitochondrial transmembrane potential (FL2/FL1 ratio) (E), and PS
exposure (FITC-annexin V binding) (F) in platelets pretreated with calpeptin (Calpt. 75 M and 150 M) and PSI (25 M), PSI (25 M) alone, CCCP (30 M),
thrombin (1 unit/ml), or DMSO (RP), as indicated. *, p 0.05 compared with DMSO-pretreated platelets; #, p 0.05 compared with PSI-pretreated platelets.
Data are representative of five different experiments and are expressed as mean S.D. (error bars).
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cells, which reflects facilitated phagocytic uptake of platelets
upon proteasomal inhibition (Fig. 5B).
DISCUSSION
The results presented so far identify the proteasome pepti-
dase complex as a novel regulator of platelet life span. A puta-
tive internal “timer” comprising anti- and pro-apoptotic factors
of Bcl-2 family has been suggested as a determinant of platelet
longevity through apoptosis induction (7, 8). The present study,
while contributing further evidence in support of control of
platelet life span by Bcl-2 family proteins, introduces protea-
some system as an essential and additional component of this
timer.
The role of proteasome in regulation of cellular apoptosis has
been well documented (34–38). Cellular levels of Bcl-2, Bcl-XL,
and Bax are regulated by proteasomal activity in endothelial
cells and cancer cell lines (20–22). Here, we show that platelets
exhibited features of apoptosis following inhibition of protea-
somal peptidase activity, which included drop in m,
enhanced surface exposure of PS, and rise in cytosolic ROS.
Platelets abundantly express Bax (39) as well as the Bax-specific
mRNA (40). Because Bax is a known substrate of proteasome
(22), we evaluated the effect of proteasome inhibition on its
levels. PSI-treated platelets were found to possess significantly
higher levels of functionally active Bax than their control
(untreated) counterparts although there was no significant dif-
ference in levels of total Bax. Further, we found that active Bax
was being constitutively polyubiquitinated in resting platelets
and thus targeted to proteasome.Wewere also able to establish
Bax as a mediator of platelet cell death induced upon protea-
somal inhibition using its peptide inhibitor V5. It reversed the
apoptotic features in washed platelets as well as the drop in
platelet life span in mice that were induced by PSI. The accu-
mulation of conformationally active Bax also led to its increased
localization tomitochondrialmembrane. However, this did not
translate into release of mitochondrial cytochrome c into cyto-
sol or activation of caspase-3. These results are consistent with
existence of caspase-independent cell death pathways that have
been described in white blood cells as well as platelets (19, 29,
30, 31, 41). There has also been evidence of calpain, a calcium-
dependent protease, to be activated in stored platelets under-
going caspase-independent apoptosis reflective of its role in
mediating cell death (31). In concurrence with these findings
we found that platelets exhibited higher calpain activity upon
treatment with proteasome inhibitors. Because Bax is known to
induce release of calcium stores in endoplasmic reticulum into
the cytoplasm (32) we examined intracellular calcium levels
that determine calpain activity and found it to be significantly
elevated after treating plateletswith proteasome inhibitors (Fig.
4D). Calpeptin, a specific calpain inhibitor, partially reversed
the effects of proteasome inhibition on plalelet m and PS
exposure (Fig. 4, E and F), consistent with a causal role of cal-
pain in mediating cell death.
We explored whether proteasome inhibition would
adversely affect platelet life span in vivo in a rodent model.
Administration ofmicewith PSI led to thrombocytopenia. This
was associated with reduced half-life of platelets and increased
number of young reticulated cells in circulation, indicative of
enhanced rate of platelet clearance in PSI-administered mice.
Also, administration of oleuropien, a small molecule protea-
some activator, brought about a modest increase in platelet
half-life. Consistentwith this, PSI-treated humanplatelets were
found to be phagocytosed more efficiently by macrophages, as
demonstrated in vitro from flow cytometry and epifluorescence
microscopy studies.
The present study indicates that proteasomal peptidase
activity promotes platelet survival through constitutive elimi-
nation of the conformationally active Bax. Proteasome enzymic
function is known to decline with cell aging (42, 43), which
would lead to accumulation of pro-apoptotic proteins like Bax
in platelets. Thus, progressive attenuation in activities of either
Bcl-XL (7, 8) or proteasome in aging cells would result in unre-
strained activity of pro-apoptotic Bax/Bak, eventually leading
to platelet cell death and phagocytic clearance. Apart from the
obvious relevance to platelet physiology, this study would also
have translational implications. Pharmacological intervention
using activators such as oleuropein (44) or genetic modulation
to overexpress proteasome activator subunits to promote pro-
teasomal activity could prove clinically beneficial as it would
favor platelet survival in conditions like thrombocytopenia and
transfusion of stored platelets. On the other hand, proteasome
inhibitors may be exploited as therapeutic strategy to induce
platelet apoptosis and thus to reduce severity of thrombosis.
Our observations also call for careful consideration of potential
adverse effect on platelet life span while exploiting the benefits
of proteasomal inhibition in cancer therapeutics.
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